key: cord-0801304-un4c5s3x
authors: Kneller, Daniel W.; Galanie, Stephanie; Phillips, Gwyndalyn; O'Neill, Hugh M.; Coates, Leighton; Kovalevsky, Andrey
title: Malleability of the SARS-CoV-2 3CL Mpro active site cavity facilitates binding of clinical antivirals
date: 2020-10-23
journal: Structure
DOI: 10.1016/j.str.2020.10.007
sha: 1d03f46014214821d48f88606193b84979d7043a
doc_id: 801304
cord_uid: un4c5s3x

The COVID-19 pandemic caused by SARS-CoV-2 requires rapid development of specific therapeutics and vaccines. SARS-CoV-2 main protease, 3CL Mpro, is an established drug target for the design of inhibitors to stop the virus replication. Repurposing existing clinical drugs can offer a faster route to treatments. Here, we report on the binding mode and inhibition properties of several inhibitors using room-temperature X-ray crystallography and in vitro enzyme kinetics. The enzyme active site cavity reveals a high degree of malleability, allowing aldehyde leupeptin and hepatitis C clinical protease inhibitors (telaprevir, narlaprevir, and boceprevir) to bind and inhibit SARS-CoV-2 3CL Mpro. Narlaprevir, boceprevir and telaprevir are low micromolar inhibitors, whereas the binding affinity of leupeptin is substantially weaker. Repurposing hepatitis C clinical drugs as COVID-19 treatments may be a useful option to pursue. The observed malleability of the enzyme active site cavity should be considered for the successful design of specific protease inhibitors.

The etiological agent of the COronaVIrus is the novel human coronavirus SARS-CoV-2, the origin of which is still being debated. Nonetheless, has become a pandemic of extraordinary proportions causing worldwide disruptions in travel, economic activity, and social life (Belongia and Osterholm, 2020; Lotfi et al., 2020 , Helmy et al., 2020 Wu et al., 2020; Rastogi et al., Coronaviridae Study Group, 2020; Liu et al., 2020) . SARS-CoV-2 is an enveloped positive-sense single-stranded RNA virus having one of the largest genomes of ~30 kilobases. SARS-CoV-2 is very similar to the earlier SARS-CoV that was responsible for a 2003 outbreak; the viruses share ~80% genomic identity, and certain proteins encoded in the viral genomes are over 90% homologous (Xu et al., 2020) .

SARS-CoV-2 replication involves the synthesis of two large polyproteins pp1a and pp1ab (~450 kDA and ~790 kDa, respectively), which are inactive until the viral chymotrypsinlike cysteine protease enzyme (3CL M pro or main protease) cleaves them into smaller functional proteins (Gorbalenya and Snijder, 1996; Muramatsu et al., 2016) . 3CL M pro is thus indispensable for the viral lifecycle, and its inhibition can prevent the production of infectious virions. The lack of homologous human proteins and the vital role of the enzyme for SARS-CoV-2 replication makes it one of the most promising targets for the design of specific protease inhibitors (Dai et al., 2020; Zhang et al., 2020; Jin et al., 2020a; Pillaiyar et al., 2016; Wang et al.,2017; Yang et al., 2005) . The design of new antivirals and their development for clinical use may take years, emphasized by the fact that no SARS-CoV protease inhibitors have been FDA-approved after more than a decade of research efforts. Conversely, repurposing of known clinical drugs developed for the treatment of other diseases may provide rapid therapeutic intervention to battle COVID-19 in emergency situations and, possibly, preexposure prophylaxis against the SARS-CoV-2 infection (Huang et al., 2020; Jean and Hsueh, 2020) .

Here, we present crystallographic and inhibition kinetics evidence for the SARS-CoV-2 3CL M pro inhibition by three hepatitis C clinical NS3/4A serine protease inhibitors (Scheme 1), telaprevir (Incivek TM , Vertex Pharmaceuticals; Kwong et al., 2019) , boceprevir (Victrelis TM , Merck; Venkatraman, 2019), and narlaprevir (Arlansa TM , R-Pharm, Russia; de Bruijne et al., 2010; Isakov et al., 2016) , and a naturally occurring microbial peptide aldehyde leupeptin (Appleyard and Tisdale, 1985) . We chose these compounds because of their peptidomimetic chemical nature and capability to act as reversible covalent inhibitors. We, therefore, hypothesized that they should bind to and inhibit SARS-CoV-2 3CL M pro . Our near-J o u r n a l P r e -p r o o f physiological room-temperature X-ray crystallographic structures establish the mechanism of action for these reversible covalent peptidomimetic inhibitors and demonstrate a unique ability of the enzyme active site cavity to accommodate a variety of chemical groups by substantially distorting its shape and size compared to the ligand-free state (Kneller et al., 2020) through conformational changes in the P2 helix (residues 46-50), the P4 β-hairpin flap (residues [165] [166] [167] [168] [169] [170] and P5 loop (residues 189-194) ( Figure 1 ). All four inhibitors bind in a stereospecific fashion, with only the S-enantiomers observed for their covalent hemithioacetal and hemithioketal linkages, utilizing the available enzyme's substrate binding subsites S1' through S5. Solution measurements demonstrate that hepatitis C clinical compounds are low micromolar inhibitors, whereas leupeptin has the lowest affinity to SARS-CoV-2 3CL M pro . Our results, therefore, lay a foundation for possible repurposing of the hepatitis C clinical drugs that were originally developed for the inhibition of hepatitis C NS3/4A protease. Our structural data also emphasize the requirement to consider the observed significant malleability of the enzyme's active site cavity in the structure-assisted and computational design of improved specific 3CL M pro inhibitors.

Leupeptin binds to SARS-CoV-2 3CL M pro in a stereospecific fashion. SARS-CoV-2 3CL M pro shares 96% sequence homology and has similar catalytic efficiency to that of the SARS-CoV enzyme. Its tertiary structure consists of the catalytic domains I, II, and the helical domain III ( Figure 1 ) (Xu et al., 2020; Muramatsu et al., 2016; Dai et al., 2020; Xue et al., 2007; Huang et al., 2004) . The non-canonical catalytic dyad with residues Cys145 and His41 is buried in the active site cavity that is located on the surface of the protein flanked by residues from both domains I and II. The active dimer has a two-fold axis that goes from top to bottom between the two monomers ( Figure 1 ) and frequently occurs as a crystallographic two-fold axis. The Cterminal aldehyde group of leupeptin, N-acetyl-L-leucyl-L-leucyl-L-argininal (Ac-Leu-Leu-Arg-CHO, Scheme 1), readily reacts with Cys145 forming a hemithioacetal, with the aldehyde carbon atom becoming sp 3 hybridized. P1 arginine and the P2 and P3 leucine side chains bind in the substrate binding subsites S1, S2, and S3, respectively. Although the aldehyde can freely rotate in leupeptin, it reacts with Cys145 in SARS-CoV-2 3CL M pro in a stereospecific fashion. Only the S-enantiomer is observed in the electron density maps, with the hemithioacetal oxygen facing the enzyme's oxyanion hole (Menard and Storer, 1992) and making hydrogen bonds with the J o u r n a l P r e -p r o o f main chain amide nitrogens of Gly143 and Cys145 (Figure 2A ). The geometry of the hemithioacetal suggests that its oxygen atom is deprotonated and thus negatively charged. The charge is partially stabilized by the hydrogen bonds with the oxyanion hole residues. The hemithioacetal moiety of leupeptin bound to Cys145 has the same geometry as the tetrahedral intermediate that forms along the peptide bond hydrolysis reaction pathway catalyzed by this enzyme. This tetrahedral intermediate is necessarily metastable as it spontaneously collapses into the acyl intermediate. Therefore, the hemiacetal linkage of leupeptin to Cys145 is probably also metastable, reducing the stability of the complex. Leupeptin makes three more direct hydrogen bonds with the main chain atoms of His164 and Glu166 and a water-mediated interaction with the side chain of Glu189 ( Figure 3A) . Interestingly, the ligand makes no direct hydrogen bonds with side chains of SARS-CoV-2 3CL M pro . The P1 arginine side chain of leupeptin fits in the hydrophilic S1 substrate binding subsite but makes no hydrogen bonds with the enzyme residues.

In contrast, the P2 leucine fits well in the hydrophobic S2 subsite, and P3 leucine faces the bulk solvent.

We observe that binding of leupeptin to SARS-CoV-2 3CL M pro results in significant conformational changes in several structural elements relative to their geometry in the ligandfree enzyme ( Figure S1A ) (Kneller et al., 2020) . The P2 helix and the tip of the P4 β-hairpin flap shift their positions in the leupeptin-bound structure to expand the active site cavity. The distance between Ser46 and Pro168 Cα atoms increases from 15.7 Å in the ligand-free structure to 17.1 Å when leupeptin is present. Met49 and Met165 side chains move away from leupeptin to accommodate the chemical groups in positions P2 and P4 of the inhibitor. Conversely, the P5 loop does not move due to the lack of P5 substituent in leupeptin.

Binding of hepatitis C protease inhibitors to SARS-CoV-2 3CL M pro . Telaprevir, narlaprevir, and boceprevir are β-ketoamide inhibitors and have a ketone warhead that undergoes a nucleophilic attack by the Cys145 thiolate to form a hemithioketal. Telaprevir and narlaprevir possess substituents in six positions, including chemical groups at P1ʹ and P1 through P5, whereas boceprevir lacks a chemical group at P5 (Scheme 1). The P1ʹ amides of these inhibitors occupy the S1ʹ substrate binding subsite, and the amide carbonyl oxygens make hydrogen bonds with the enzyme's oxyanion hole. Similar to leupeptin, the drugs bind stereospecifically, with only the S-enantiomer visible in the electron density maps ( Figure 2B -2D). But unlike leupeptin, the hemithioketal oxygens point away from the oxyanion hole allowing the formation of strong J o u r n a l P r e -p r o o f hydrogen bonds with His41 imidazole side chains with the distances of 2.4-2.8 Å ( Figure 3B -3D), with boceprevir forming the shortest and narlaprevir the longest hydrogen bonds. Such orientation of the hemithioketal groups suggests that their oxygens may be protonated through the abstraction of a hydrogen from His41. The 2.4 and 2.5 Å hydrogen bonds made by boceprevir and telaprevir also indicate the possible formation of low-barrier hydrogen bonds between their hemithioketal oxygens and the histidine Nε2 imidazole nitrogens. It is evident that the presence of P1' amide groups in these inhibitors determines the stereospecificity of the hemithioketal formation, directing oxygen atom towards His41 so that the P1ʹ amide carbonyl can form hydrogen bonds with the oxyanion hole. Moreover, the neutrally charged hemithioketal groups would be more stable than the negatively charged hemithioacetal of bound leupeptin, if indeed His41 protonates the hemithioketal oxygen.

Because telaprevir, narlaprevir and boceprevir are peptidomimetic inhibitors with similar structures, they make very similar hydrogen bonds with the main chain atoms of His164 and telaprevir complex. Thus, the side chain of Gln189 can be considered a hydrogen bond partner for an inhibitor's P3 group. The S4 subsite has both hydrophilic and hydrophobic groups.

Met165, Leu167 and Phe185 make up the hydrophobic wall towards the interior of the protein, whereas the main chain carbonyls of Val186, Arg188, and Thr190 and the side chain of Gln192 provide the hydrophilic wall at the enzyme's surface. The S4 subsite may therefore prefer inhibitors with amphiphilic P4 groups, e.g. saturated heterocycles.

Hepatitis C protease inhibitors reshape the 3CL M pro active site cavity. The structures of the four inhibitor complexes were superimposed on our previously published room-temperature Xray structure (Kneller et al., 2020) of the ligand-free SARS-CoV-2 3CL M pro to visualize how the inhibitors change the conformation of the active site cavity (Figure 4 and S1B-S1D). The inhibitors have a significant effect on the enzyme's active site cavity geometry. There are dramatic shifts in the positions of the P2 helix, the tip of the P4 β-hairpin flap, and the P5 loop when inhibitors are bound relative to the ligand-free enzyme. Leupeptin is the smallest of the four inhibitors studied, causing the least conformational distortions. Telaprevir, narlaprevir, and boceprevir have a larger effect on the active site cavity, with each resulting in unique active site conformations due to differing inhibitor side chains. Telaprevir pushes the P2 helix the farthest by ~ 1.5 Å, whereas the tip of the P4 β-hairpin flap shifts the most under the steric pressure from boceprevir by ~ 2.4-2.6 Å. Narlaprevir, on the other hand, causes the end of the P5 loop (residue Ala193) to move away by ~ 2 Å due to the presence of the bulky P5 tert-butylsulfoxide group, but telaprevir makes the start of the P5 loop (residue Gln189) shift the most by ~ 1.1 Å. Therefore, the SARS-CoV-2 3CL M pro active site cavity shows significant malleability as it can change its shape and expand by as much as 3.4 Å between P2 helix and the tip of the P4 βhairpin flap, and by as much as 2.5 Å between the tip of the P4 β-hairpin flap and the P5 loop ( Figure 4) .

Comparison of the SARS-CoV-2 3CL M pro complexes studied here with those containing covalent ketoamide inhibitor 13b (PDB ID 6Y2F, Zhang et al., 2020) and aldehyde inhibitor GC-376 (PDB ID 6WTT, Ma et al., 2020) demonstrates similar conformational changes observed in the active site cavity ( Figure S4 ), indicating that SARS-CoV-2 3CL M pro active site cavity has an intrinsic ability to adapt its conformation to different chemical groups of inhibitors. Also, we note that telaprevir, narlaprevir and boceprevir bind with the same stereochemistry to the J o u r n a l P r e -p r o o f catalytic Ser of the hepatitis C NS3/4A serine protease as they do in SARS-CoV-2 3CL M pro , having their hemiketal oxygen atoms directed towards and hydrogen bonded with the catalytic His and their P1ʹ amide carbonyl groups hydrogen bonded with the oxyanion hole residues (Prongay et al., 2007; Romano et al., 2012) . The aliphatic P1 groups of the three inhibitors are positioned in the hydrophobic substrate binding subsite S1 in the hepatitis C protease, whereas subsite S1 is more hydrophilic in SARS-CoV-2 3CL M pro . Unlike their binding mode in SARS-CoV-2 3CL M pro , the other chemical groups of these inhibitors are located on the surface of the hepatitis C protease.

measurements of the SARS-CoV-2 3CL M pro activity in vitro using a FRET substrate gave the k cat /K m value of 1600 s -1 ·M -1 , which is in agreement with the previously reported values ( Figure   S2 ) Ma et al., 2020) . As expected, the inhibition kinetics measurements demonstrated that leupeptin is the lowest affinity inhibitor of the four assayed with an IC50 of 92 µM, 95% confidence interval (CI) of 80 to 106 µM ( Figure S3 ). The three hepatitis C protease inhibitors efficiently inhibit SARS-CoV-2 3CL M pro activity with micromolar affinity. (Ma et al., 2020) . Initial binding of a covalent inhibitor is followed by covalent bond formation with the rate constant k 2 . Similar to the previous report (Ma et al., 2020), we were not able to obtain accurate values of k 2 due to substrate depletion prior to the equilibrium between the non-covalent and covalent enzyme-inhibitor complexes. Although the three studied hepatitis C inhibitors are not specific SARS-CoV-2 3CL M pro inhibitors, their affinities, nonetheless, appear to be similar to those of many protease inhibitors that have been designed to specifically target SARS-CoV 3CL M pro (Anand et al., 2003; Pillaiyar et al., 2016; Wang et al., 2017; Thanigaimalai et al., 2013; Jacobs et al., 2013; Jo et al., 2020) .

Two therapeutic intervention strategies for the treatment of COVID-19 are being considered by the scientific community. One such strategy involves the repurposing of the existing clinical drugs, which may provide a quicker route to available treatments to battle COVID-19. Although such drugs have not been specifically developed for the treatment of SARS-CoV-2 infection, they may prove useful in alleviating the disease symptoms by inactivating SARS-CoV-2 3CL M pro , which is considered a challenging target for inhibitor design (Bzowka et al., 2020) . Knowledge of the mechanism of action for such repurposed drugs is of paramount importance. We have obtained and analyzed room-temperature X-ray structures of several peptidomimetic inhibitors in complex with SARS-CoV-2 3CL M pro and measured their effectiveness in inhibiting the enzyme. X-ray crystallography at room temperature, which is close to the physiological temperature of ~37°C, has gained appreciation in recent years because low-temperature structures may not provide representative conformational states of the protein or a bound ligand and may contain artifacts due to the required use of cryo-protectant chemicals and temperature effects (Fraser et al., 2011; Keedy et al., 2014; Kovalevsky et al., 2018; Otten et al., 2018; Gerlits et al., 2019a; Kneller et al., 2020) . The structures reported here provide evidence that the studied hepatitis C clinical drugs can bind to SARS-CoV-2 3CL M pro, and enzyme inhibition kinetics measurements demonstrate that they are micromolar inhibitors of the protease. Boceprevir and narlaprevir have the highest affinities to SARS-CoV-2 3CL M pro and, perhaps, can be looked at as possible treatment options. For example, boceprevir and an antineoplastic drug carmofur were recently reported to inhibit SARS-CoV-2 viral replication in cell culture (Ma et al., 2020; Jin et al., 2020b) . We also observed significant malleability of the SARS-CoV-2 3CL M pro active site, including P2 helix, the tip of the P4 β-hairpin flap, and the P5 loop, that permits the inhibitor molecules to reshape the binding cavity. The flexibility of these secondary structure elements allows the inhibitors to efficiently bind to SARS-CoV-2 3CL M pro , but it should also be carefully considered in the design of the specific SARS-CoV-2 3CL M pro inhibitors. P2 helix, the tip of the P4 β-hairpin flap and the P5 loop can change their conformations independently of each other as they are seen to shift differently when the studied complexes are compared. Perhaps, SARS-CoV-2 3CL M pro active site cavity may use the ability to alter its shape to avoid interactions with the inhibitors.

In summary, we have succeeded in using room-temperature crystallography to probe the conformational flexibility of the SARS-CoV-2 3CL M pro active site cavity at near-physiological temperature that showed significant malleability accommodating inhibitors not specifically J o u r n a l P r e -p r o o f designed to target this enzyme. We were able to analyze how the active site cavity reacts to the binding of three hepatitis C clinical protease inhibitors (telaprevir, narlaprevir, and boceprevir) and a natural peptide aldehyde leupeptin. Namely, we directly observed how ligand binding induces conformational changes for the P2 helix, the tip of the P4 β-hairpin flap, and the P5 loop in the active site cavity. The conformational flexibility and dynamics of this enzyme active site cavity should be considered in drug design efforts. It also appears that the docking of small molecules fragments to the ligand-free protease structure may be a futile endeavor. Finally, our structures also point to possible improvements in the specific SARS-CoV-2 3CL M pro inhibitor design. The complex with leupeptin is shown in yellow, the complex with telaprevir in dark pink, the complex with narlaprevir in blue, and the complex with boceprevir in grey. Narlaprevir and telaprevir are represented in ball-andstick, whereas the other two inhibitors are omitted for clarity. The conformational changes for the P2 helix, the tip of the P4 β-hairpin flap and the P5 loop due to inhibitor binding are shown as red arrows and maximal shifts are indicated with values colored red. The expansion of the active site cavity is represented by black arrows and the maximal shifts are indicated with values colored black.

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Andrey Kovalevsky (kovalevskyay@ornl.gov).

The study did not generate new unique reagents.

The four protein structures have been deposited into the Protein Data Bank with accessions codes of 6XCH for the SARS-CoV-2 3CL M pro complex with leupeptin, 6XQS for the complex with telaprevir, 6XQT for the complex with narlaprevir, and 6XQU for the complex with boceprevir.

See Key Resources Table for more details.

Escherichia coli BL21 DE3 competent cells were used in this study, and the cells were grown in LB media in shaking incubators. Additional details are provided in the Method Details section. from SARS CoV-2 was cloned into pD451-SR plasmid (Atum, Newark, CA), expressed and purified according to the published procedure (Kneller et al., 2020) . To make the authentic the N-terminus, the protease sequence is flanked by the maltose binding protein followed by the 3CL M pro autoprocessing site SAVLQ↓SGFRK (arrow indicates the cleavage site) corresponding to the cleavage between NSP4 and NSP5 in the viral polyprotein. To make the authentic Cterminus, the enzyme construct codes for the human rhinovirus 3C PreScission protease cleavage site (SGVTFQ↓GP) connected to a His 6 tag. The N-terminal flanking sequence is autoprocessed during expression in E. coli (BL21 DE3), whereas the C-terminal flanking sequence is removed J o u r n a l P r e -p r o o f by the treatment with PreScission protease (Millipore Sigma, St. Louis, MO) . For crystallization, the authentic 3CL M pro is concentrated to 4-6 mg/mL.

Room-temperature X-ray crystallography quality protein crystals were grown using the sitting-drop vapor diffusion method. Ligand-free 3CL M pro at 4 mg/mL formed crystal cluster aggregates in 22% PEG3350, 0.1 M Bis-Tris pH 6.5, which were used to generate microseeds utilizing the Hampton Research Seed Bead™ kit. These ligand-free protease microseeds were used to nucleate 3CL M pro in the presence of leupeptin, boceprevir, telaprevir, or narlaprevir. 1 mg of lyophilized leupeptin dissolved directly into 250 µL of 3CL M pro at 5.4 mg/mL. Boceprevir, telaprevir, or narlaprevir dissolved in 100% dimethyl sulfoxide were mixed at 1:10 molar ratio with 3CL M pro at 5.4-5.6 mg/mL and allowed to incubate at room temperature for a minimum of 1 hour. Precipitation, if present, was removed by centrifugation prior to setting up crystal trays. All crystals obtained for this study grew in drops containing 10 µL proteinligand complex mixed with 10 µL 18-22% PEG3350, 0.1 M Bis-Tris pH 7.0 with 0.4 µL of 1:200 dilution microseeds. Single plate-shaped crystals appeared after 3 days at 14°C and were allowed to grow for an additional 4 days before harvesting them for crystallographic data collection.

X-ray data collection and structure refinement. To collect room-temperature diffraction datasets, crystals of 3CL M pro in complexes with leupeptin, telaprevir, narlaprevir or boceprevir were mounted using the MiTeGen (Ithaca, NY) room-temperature capillary setup. Room temperature X-ray crystallographic data from these crystals were collected using a Rigaku HighFlux HomeLab instrument equipped with a MicroMax-007 HF X-ray generator and Osmic VariMax optics. The diffraction images were obtained using an Eiger 4M hybrid photon counting detector. Diffraction data were integrated using the CrysAlis Pro software suite (Rigaku Inc., The Woodlands, TX). Diffraction data were then reduced and scaled using the Aimless (Evans and Murshudov, 2001) program from the CCP4 suite (Winn et al., 2011) ; molecular replacement using PDB code 6WQF (Kneller et al., 2020) was then performed with Molrep (Winn et al., 2011) from the CCP4 program suite. The refinement of each protein structure was conducted using Phenix.refine from the Phenix (Adams et al., 2010; Winn et al., 2011) suite of programs and the COOT (Emsley et al., 2010 ) molecular graphics program. The geometry of each final structure was then carefully checked with Molprobity (Chen et al., 2010) ; the data collection and refinement statics are shown in Table S1 .

Enzyme activity kinetics assay. The enzymatic activity of SARS-CoV-2 M pro was characterized by measuring initial rate with a previously established Förster resonance energy transfer (FRET) peptide substrate assay (Kuo et al., 2004) and V max of 36 nM/s, 95% CI [32, 41] , yielding a second-order rate constant of k cat /K M = 1600 s -1 M -1 ( Figure S2 ). This value is similar to those recently obtained by others , Ma et al., 2020 . 

The IC50 Figure S3) . These values are similar to the recently measured IC50 values for narlaprevir (5.7 µM) and boceprevir (4.1 µM) (Ma et al., 2020) .

For kinetics experiments, initial rates were determined by linear regression of the linear portion of enzyme reaction progress curves with <10% substrate conversion using the linest() formula in Excel. The relationships between initial rates and substrate concentration and between initial rates and inhibitor concentration were determined by nonlinear regression using GraphPad Prism 8.4.3. Statistical details including best-fit values for K M , V max , and IC50 and their 95% confidence intervals using the asymmetrical (profile-likelihood) method are given in Figures S2 and S3 and the associated figure legends.

PHENIX: a comprehensive Python-based system for macromolecular structure solution

Coronavirus main protease (3CL pro ) structure: basis for design of anti-SARS drugs

Inhibition of the growth of human coronavirus 229E by leupeptin

COVID-19 and flue, a perfect storm

Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients

Structural and evolutionary analysis indicate that the SARS-CoV-2 M pro is a challenging target for smallmolecule inhibitor design

MolProbity: all-atom structure validation for macromolecular crystallography

The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease

Features and development of Coot

How good are my data and what is the resolution?

Accessing protein conformational ensembles using room-temperature X-ray crystallography

Productive reorientation of a bound oxime reactivator revealed in room temperature X-ray structures of native and VX-inhibited human acetylcholinesterase

Viral cysteine proteases

The COVID-19 pandemic: A ccomprehensive review of taxonomy, genetics, epidemiology, diagnosis, treatment, and control

A review of therapeutic agents and Chinese herbal medicines against SARS-COV-2 (COVID-19)

3C-like Proteinase from SARS Coronavirus Catalyzes Substrate Hydrolysis by a General Base Mechanism

Pharmacokinetics of the new hapatitis C virus NS3

protease inhibitor narlaprevir following single-dose use with or without ritonavir in patients with liver cirrhosis

Discovery, synthesis, and structure-based optimization of a series of N-(tert-butyl)-2-(N-arylamido)-2-(pyridin-3yl) acetamides (ML188) as potent noncovalent small molecule inhibitors of the severe acute respiratory syndrome coronavirus (SARS-CoV) 3CL protease

Old and re-purposed drugs for the treatment of COVID-19

Structure of Mpro from COVID-19 virus and discovery of its inhibitors

Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur

Inhibition of SARS-CoV 3CL protease by flavonoids

Crystal cryocooling distorts conformational heterogeneity in a model Michaelis complex of DHFR

Structural plasticity of SARS-CoV-2 3CL M pro active site cavity revealed by room temperature X-ray crystallography

To be or not to be' protonated: atomic details of human carbonic anhydrase-clinical drug complexes by neutron crystallography and simulation

Characterization of SARS main protease and inhibitor assay using a fluorogenic substrate

Development and Marketing of INCIVEK (Telaprevir; VX-950): A First-Generation HCV Protease Inhibitor

HCV: The Journey from Discovery to a Cure

Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases

COVID-19:transmission, prevention, and potential therapeutic opportunities

GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease

Oxyanion hole interactions in serine and cysteine protease

SARS-CoV 3CL protease cleaves its C-terminal autoprocessing site by novel subsite cooperativity

Rescue of conformational dynamics in enzyme catalysis by directed evolution

An overview of severe acute respiratory syndrome-coronavirus (SARS-CoV) 3CL protease inhibitors: peptidomimetics and small molecule chemotherapy

The novel coronavirus 2019-nCoV: its evolution and transmission into humans causing global COVID-19 pandemic

The molecular basis of drug resistance against hepatisis C virus NS3/4A protease inhibitors

Development of potent dipeptide-type SARS-CoV 3CL protease inhibitors with novel P3 scaffolds: Desing, synthesis, biological evaluation, and docking studies

Discovery of Boceprevir, a Ketoamide-Derived HCV NS3 Protease Inhibitor, for Treatment of Genotype 1 Infections

Discovery of unsymmetrical aromtic disulfides as novel inhibitors of SARS-CoV main protease: Chemical synthesis, biological evaluation, molecular docking and 3D-QSAR study

Overview of the CCP4 suite and current developments

A new coronavirus associated with human respiratory disease in China

Systematic comparison of two animal-to-human transmitted human coronaviruses: SARS-CoV-2 and SARS-CoV

Production of authentic SARS-CoV Mpro with enzhanced activity: Application as a novel tagcleavage endopeptidase for protein overexpression

Desing of wide-spectrum inhibitors targeting coronavirus main proteases

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors